Biotech Values

[DewDiligence]

NICE seeks to expedite endorsement of drugs with lowest cost/QALY:

http://www.reuters.com/article/us-pharmaceuticals-britain-nice-idUSKCN12D2A7

The National Institute for Health and Care Excellence (NICE) said on Thursday that treatments offering exceptional value for money could be cleared for National Health Service use nearly three months earlier than at present under the new process.

The system will apply to treatments with a likely cost per quality adjusted life year (QALY) of up to…[$12,500]. For these products, final NICE guidance would be published immediately after a drug wins its official marketing license.

$12,500/QALY is a stringent threshold, so it seems doubtful that many new drugs will be efficacious, tolerable, and cheap enough to meet it.